ORBi: Detailled Reference

Short communication (Scientific journals)

Quel futur pour les cellules-souches mésenchymateuses dans les affections ostéoarticulaires ?

HAUZEUR, Jean-Philippe

2020 • In Revue du Rhumatisme Monographies

Permalink
https://hdl.handle.net/2268/246063

DOI
10.1016/j.monrhu.2020.02.003

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Hauzeur_Quel-futur-pour-les-cellulessouches_2020.pdf

Publisher postprint (487.94 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cell-based therapy; MSC; Osteoarthritis; Osteonecrosis; Osteoporosis; Stem cell

Abstract :

[en] Regenerative medicine using mesenchymal stem cells (MSC) is developped in several musculoskeletal diseases. The concentration of bone marrow or adipose tissue has been the most common therapeutic method used. The large variability of the cell-productions, however, could be a limitation. Recent biological research concerning MSC has unearthed several new aspects. Firstly, a heterogeneity of the MSC was found following the tissue origin and/or the patient's. Then, the characterisation of MSC was improved by using new combinations of cellular membrane markers. Another important step was the discovery of the paracrine activity of MSC. The MSCs are able to produce a lot of growth factors and cytokines, a production of extra cellular vesicles like exosomes arising an intercellular signaling. MSCs were found to have not only a proliferation and differentiation performance to restore the damages of time, but also immunomodulation and anti-inflammation activities. The field of cell-based therapy with MSC is enlarged with newer and more promising methods than bone marrow concentrate. Expansion culture methods of MSC have been developped, as in vitro differentiation in osteoblasts and chondrocytes or cell manipulations by transfection to produce induced pluripotent stem cells or super MSCs able to produce more growth factors or cytokines, or to modify the membrane signaling for improving MSC homing. The translation of these biological developments in human therapy is the key for the MSC future. After pre-clinical tests to verify the safety, controlled trials are needed to define the true place of this regenerative medicine. © 2020 Société Française de Rhumatologie

Disciplines :

Hematology

Author, co-author :

HAUZEUR, Jean-Philippe ; Université de Liège - ULg

Language :

French

Title :

Quel futur pour les cellules-souches mésenchymateuses dans les affections ostéoarticulaires ?

Alternative titles :

[en] What future for mesenchymal stem cells in musculoskeletal diseases?

Publication date :

2020

Journal title :

Revue du Rhumatisme Monographies

ISSN :

1878-6227

eISSN :

2212-0920

Publisher :

Elsevier Masson, Paris, France

Available on ORBi :

since 17 March 2020

Statistics

Number of views

75 (10 by ULiège)

Number of downloads

7 (7 by ULiège)

More statistics

Scopus citations^®

0

Scopus citations^®
without self-citations

0

OpenCitations

0

Bibliography

Friedenstein, A.J., Chailakhjan, R.K., Lalykina, K.S., The development of fibroblast colonies in mono-layer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3 (1970), 393–403.
Caplan, A.I., Mesenchymal stem cells. J Orthop Res 9 (1991), 641–650.
Gangji, V., Hauzeur, J.P., Matos, C., et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 86 (2004), 1153–1160.
Hernigou, P., Beaujean, F., Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 405 (2002), 14–23.
Hernigou, H., Poignard, A., Beaujean, F., et al. Percutaneous autologous bone-marrow grafting for non-unions: influence of the number and concentration of progenitor cells. JBJS A 87 (2005), 1430–1437.
Zuk, P.A., Zhu, M., Mizuno, H., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7 (2001), 211–228.
De Bari, C., Dell'Accio, F., Tylzanowski, P., et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 44 (2001), 1928–1942.
Gronthos, S., Mankani, M., Brahim, J., et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A 97 (2000), 13625–13630.
Zhang, Y., Grosfeld, E.C., Camargo, W.A., et al. Efficacy of intraoperatively prepared cell-based constructs for bone regeneration. Stem Cell Res Ther, 9, 2018, 283.
Parker, A.M., Katz, A.J., Adipose-derived stem cells for the regeneration of damaged tissues. Expert Opin Biol Ther 6 (2006), 567–578.
Qadan, M.A., Piuzzi, N.S., Boehm, C., et al. Variation in primary and culture-expanded cells derived from connective tissue progenitors in human bone marrow space, bone trabecular surface and adipose tissue. Cytotherapy 20 (2018), 343–360.
Dominici, M., Le Blanc, K., Mueller, I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006), 315–317.
Mendicino, M., Bailey, A.M., Wonnacott, K., et al. MSC-based product characterisation for clinical trials: an FDA perspective. Cell Stem Cell 14 (2014), 141–145.
Sacchetti, B., Funari, A., Remoli, C., et al. No identical “mesenchymal stem cells” at different times and sites: human-committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Rep 6 (2016), 897–913.
Rodeo, S.A., Cell therapy in Orthopaedics: where are we in 2019?. Bone Joint J 101 (2019), 361–364.
Caplan, A.I., Mesenchymal stem cells: time to change the name!. Stem Cells Transl Med 6 (2017), 1445–1451.
Presen, D.M., Traweger, A., Gimona, M., et al. Mesenchymal stromal cell-based bone regeneration therapies: from cell transplantation and tissue engineering to therapeutic secretomes and extracellular vesicles. Front Bioeng Biotechnol, 7, 2019, 352, 10.3389/fbioe.2019.00352.
Reumann, M.K., Linnemann, C., Aspera-Werz, R.H., et al. Donor site location is critical for proliferation, stem cell capacity and osteogenic differentiation of adipose mesenchymal stem/stromal cells: implications for bone tissue engineering. Int J Mol Sci, 19, 2018 [pii: E1868].
Brennan, M.A., Renaud, A., Guilloton, F., et al. Inferior in vivo osteogenesis and superior angiogenesis of human adipose-derived stem cells compared with bone marrow-derived stem cells cultured in xeno-free conditions. Stem Cells Transl Med 6 (2017), 2160–2172.
Sipp, D., Robey, P.G., Turner, L., Clear up this stem-cell mess. Nature 561 (2018), 455–457.
Galipeau, J., Krampera, M., Barrett, J., et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 18 (2016), 151–159.
Jeppesen, D.K., Fenix, A.M., Franklin, J.L., et al. Reassessment of exosome composition. Cell 4 (2019), 428–445.
Gangji, V., Hauzeur, J.P., Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Technical note. J Bone Joint Surg Am 87-A (2005), 106–112.
Wang, B.L., Sun, W., Shi, Z.C., et al. Treatment of non-traumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch Orthop Trauma Surg 130 (2010), 859–865.
Papakostidis, C., Tosounidis, T.H., Jones, E., et al. The role of “cell therapy” in osteonecrosis of the femoral head. A systematic review of the literature and meta-analysis of 7 studies. Acta Orthop 87 (2016), 72–78.
Hauzeur, J.P., De Maertelaer, V., Baudoux, E., et al. Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomised controlled double-blind trial. Int Orthop 42 (2018), 1429–1435.
Killington, K., Mafi, R., Mafi, P., et al. A systematic review of clinical studies investigating mesenchymal stem cells for fracture non-union and bone defects. Curr Stem Cell Res Ther 13 (2018), 284–291.
Nam, Y., Rim, Y.A., Lee, J., et al. Current therapeutic strategies for stem cell-base cartilage regeneration. Stem Cells Int, 25, 2018, 8490489, 10.1155/2018/8490489 [eCollection 2018].
De Becker, A., Van Riet, I., De Becker, A., et al. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy?. World J Stem Cells 8 (2016), 73–87.
Hernigou, P., Guerin, G., Homma, Y., et al. History of concentrated or expanded mesenchymal stem cells for hip osteonecrosis: is there a target number for osteonecrosis repair?. Int Orthop 42 (2018), 1739–1745.
Vanlauwe, J.J., Claes, T., Van Assche, D., et al. Characterised chondrocyte implantation in the patellofemoral joint: an up to 4-year follow-up of a prospective cohort of 38 patients. Am J Sports Med 40 (2012), 1799–1807.
Hauzeur, J.P., Bernard, C., Egrise, D., et al. 111Indium-oxine labelling for evaluating the homing process of autologous osteoblasts implanted percutaneously in atrophic non-union fractures. Int Orthop 37 (2013), 131–136.
Hauzeur, J.P., Lechanteur, C., Baudoux, E., et al. Cell Therapy Improve the Prognosis of Pre-fracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial. Clin Orthop Relat Res, 2019, 10.1097/CORR.0000000000001107.
Su, P., Tian, Y., Yang, C., et al. Mesenchymal stem cell migration during bone formation and bone diseases therapy. Int J Mol Sci, 2018, 19, 10.3390/ijms19082343 [pii: E2343].
Sattwika, P.D., Mustafa, R., Paramaiswari, A., et al. Stem cells for lupus nephritis: a concise review of current knowledge. Lupus 27 (2018), 1881–1897.
Liu, R., Zhao, P., Tan, W., et al. Cell therapies for refractory rheumatoid arthritis. Clin Exp Rheumatol 36 (2018), 911–919.
Rios Rodriguez, V., Llop, M., Poddubnyy, D., Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis?. Immunotherapy 9 (2017), 899–911.

Similar publications